Abstract | BACKGROUND: METHODS: In a single-blind, controlled study, 70 companion dogs with bone cancer pain were randomized to standard-of-care analgesic therapy alone (control, n=35) or intrathecal SP-SAP (20-60 µg) in addition to standard-of-care analgesic therapy (n=35). Activity, pain scores, and videography data were collected at baseline, 2 weeks postrandomization, and then monthly until death. RESULTS: Although the efficacy results at the 2-week postrandomization point were equivocal, the outcomes evaluated beyond 2 weeks revealed a positive effect of SP-SAP on chronic pain management. Significantly, more dogs in the control group (74%) required unblinding and adjustment in analgesic protocol or euthanasia within 6 weeks of randomization than dogs that were treated with SP-SAP (24%; P<0.001); and overall, dogs in the control group required unblinding significantly sooner than dogs that had been treated with SP-SAP (P<0.01). CONCLUSION:
|
Authors | Dorothy Cimino Brown, Kimberly Agnello |
Journal | Anesthesiology
(Anesthesiology)
Vol. 119
Issue 5
Pg. 1178-85
(Nov 2013)
ISSN: 1528-1175 [Electronic] United States |
PMID | 24195949
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- Ribosome Inactivating Proteins, Type 1
- substance P-saporin
- Substance P
- Saporins
|
Topics |
- Animals
- Behavior, Animal
- Bone Neoplasms
(complications, veterinary)
- Dog Diseases
(drug therapy)
- Dogs
- Double-Blind Method
- Injections, Spinal
- Lameness, Animal
(drug therapy, psychology)
- Motor Activity
(physiology)
- Pain Measurement
(drug effects)
- Pain, Intractable
(drug therapy, etiology, veterinary)
- Prospective Studies
- Ribosome Inactivating Proteins, Type 1
(therapeutic use)
- Saporins
- Substance P
(analogs & derivatives, therapeutic use)
- Treatment Outcome
|